How are EXEL strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the EXEL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 37.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$470.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a EXEL strangle?

The breakeven for the EXEL strangle priced on this page is roughly $43.30 and $59.70 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EXEL market-implied 1-standard-deviation expected move is approximately 10.66%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current EXEL implied volatility affect this strangle?

EXEL ATM IV is at 37.20% with IV rank near 40.53%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

EXEL Strangle Strategy

EXEL (Exelixis, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F.

EXEL (Exelixis, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $12.89B, a trailing P/E of 15.90, a beta of 0.39 versus the broader market, a 52-week range of 33.76-51.48, average daily share volume of 2.8M, a public-listing history dating back to 2000, approximately 1K full-time employees. These structural characteristics shape how EXEL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.39 indicates EXEL has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on EXEL?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current EXEL snapshot

As of May 15, 2026, spot at $50.18, ATM IV 37.20%, IV rank 40.53%, expected move 10.66%. The strangle on EXEL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 98-day expiry.

Why this strangle structure on EXEL specifically: EXEL IV at 37.20% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 10.66% (roughly $5.35 on the underlying). The 98-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated EXEL expiries trade a higher absolute premium for lower per-day decay. Position sizing on EXEL should anchor to the underlying notional of $50.18 per share and to the trader's directional view on EXEL stock.

EXEL strangle setup

The EXEL strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With EXEL near $50.18, the first option leg uses a $55.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed EXEL chain at a 98-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 EXEL shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$55.00	$2.15
Buy 1	Put	$48.00	$2.55

EXEL strangle risk and reward

Net Premium / Debit: -$470.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$470.00
Breakeven(s): $43.30, $59.70
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

EXEL strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on EXEL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$4,329.00
$11.10	-77.9%	+$3,219.60
$22.20	-55.8%	+$2,110.21
$33.29	-33.7%	+$1,000.81
$44.39	-11.5%	-$108.59
$55.48	+10.6%	-$422.02
$66.57	+32.7%	+$687.38
$77.67	+54.8%	+$1,796.78
$88.76	+76.9%	+$2,906.18
$99.86	+99.0%	+$4,015.57

When traders use strangle on EXEL

Strangles on EXEL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EXEL chain.

EXEL thesis for this strangle

The market-implied 1-standard-deviation range for EXEL extends from approximately $44.83 on the downside to $55.53 on the upside. A EXEL long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current EXEL IV rank near 40.53% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on EXEL should anchor more to the directional view and the expected-move geometry. As a Healthcare name, EXEL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to EXEL-specific events.

EXEL strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. EXEL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move EXEL alongside the broader basket even when EXEL-specific fundamentals are unchanged. Always rebuild the position from current EXEL chain quotes before placing a trade.

Frequently asked questions

What is a strangle on EXEL?: A strangle on EXEL is the strangle strategy applied to EXEL (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With EXEL stock trading near $50.18, the strikes shown on this page are snapped to the nearest listed EXEL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are EXEL strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the EXEL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 37.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$470.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a EXEL strangle?: The breakeven for the EXEL strangle priced on this page is roughly $43.30 and $59.70 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current EXEL market-implied 1-standard-deviation expected move is approximately 10.66%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on EXEL?: Strangles on EXEL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the EXEL chain.
How does current EXEL implied volatility affect this strangle?: EXEL ATM IV is at 37.20% with IV rank near 40.53%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.